<unk>  is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that is FDA approved for the treatment of locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.   Common adverse reactions include fatigue, musculoskeletal pain, constipation, decreased appetite, nausea, peripheral edema, and urinary tract infection, or cough, fatigue, pneumonitis/radiation pneumonitis, upper respiratory tract infections, dyspnea, and rash.
Durvalumab
Evolocumab
Nebacumab
Ustekinumab
Alirocumab
Dupilumab
Burosumab
Lanadelumab